Roche Holding AG (SWX:ROG)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 208.76B |
| Revenue (ttm) | 62.40B |
| Net Income (ttm) | 8.28B |
| Shares Out | 795.40M |
| EPS (ttm) | 10.31 |
| PE Ratio | 25.24 |
| Forward PE | 12.88 |
| Dividend | 9.70 (3.72%) |
| Ex-Dividend Date | Mar 27, 2025 |
| Volume | 765,479 |
| Average Volume | 1,071,327 |
| Open | 260.50 |
| Previous Close | 260.90 |
| Day's Range | 258.80 - 261.20 |
| 52-Week Range | 226.50 - 313.80 |
| Beta | 0.17 |
| RSI | 45.82 |
| Earnings Date | Jul 24, 2025 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]
Financial Performance
In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.
Financial StatementsNews
Roche moves antibiotic against superbug into Phase 3 of testing
Swiss drugmaker Roche said on Monday it would advance testing of an antibiotic against a common drug-resistant bacteria that causes serious hospital infections into the third and last phase of testing...
Roche extends trials of promising antibiotic against resistant superbug
If successful, it would be the first new class of drug against certain bacteria strains for more than 50 years
Tandem to pay Roche $36M in patent dispute settlement
Roche wins EU endorsement for metastatic breast cancer treatment
CHMP recommends EU approval of Roche's Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer
Basel, 23 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for It...
Roche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology
Basel, 23 May 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today a strategic collaboration with Broad Clinical Labs to develop and pilot groundbreaking applications using Roche's recently unvei...
New two-year follow-up of Roche's Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients
Basel, 23 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today two-year follow-up data from the phase III STARGLO study. After a median follow-up of 24.7 months, data showed a 40% improvement...
New Two-year Follow-up of Genentech's Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year follow-up data from the Phase III STARGLO study. After a med...
Roche’s Susvimo approved by FDA for diabetic retinopathy
FDA Approves Genentech's Susvimo for Diabetic Retinopathy
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo®...
FDA approves Roche's Susvimo for diabetic retinopathy
Basel, 22 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diab...
Orionis Biosciences partners with Roche's Genentech for oncology therapies
Sarepta, Roche get U.K. feedback to continue dosing in Elevidys' Duchenne trial
Genentech Provides Update on FDA Advisory Committee Meeting on Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that a U.S. Food and Drug Administration (FDA) Oncologic Drugs Adviso...
Roche provides update on FDA Advisory Committee meeting on Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
Basel, 20 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) discussed the supplemental Biologics Lice...
Trump's drug pricing order puts Roche's $50 billion U.S. investment plans at risk
President Donald Trump's executive order on drug pricing threatens Roche's planned $50 billion investment in the United States, the company said on Wednesday.
Is It Time to Invest in Europe?
Europe is being shaken out of its lethargy, militarily and otherwise, by Donald Trump's changes in U.S. policy. Should investors start buying?
Roche receives FDA approval for the VENTANA MET (SP44) RxDx Assay as the first companion diagnostic to identify non-squamous non-small cell lung cancer patients eligible for treatment with Emrelis
Basel, 14 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the FDA has approved the VENTANA® MET (SP44) RxDx Assay, the first companion diagnostic approved to aid in determining MET ...
Global Preeclampsia Diagnostics Market to Exhibit Growth at a CAGR of ~4% by 2032 | DelveInsight
New York, USA, May 14, 2025 (GLOBE NEWSWIRE) -- Global Preeclampsia Diagnostics Market to Exhibit Growth at a CAGR of ~4% by 2032 | DelveInsight The expansion of the preeclampsia diagnostics market is...
Roche reportedly warns Trump’s executive order can risk its U.S. investments
Trump's drug pricing order threatens Roche's $50 billion US investment plans, company says
U.S. President Donald Trump's executive order on drug pricing threatens Roche's planned $50 billion investment in the United States, the company said on Wednesday.
Ten-Year Data From Roche's Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17%
Roche Holdings AG (OTC: RHHBY) on Tuesday released statistically significant final overall survival (OS) results from the phase III APHINITY study in people with human epidermal growth factor recepto...
Ten-year APHINITY data show Roche's Perjeta-based regimen reduced the risk of death by 17% in people with HER2-positive early-stage breast cancer
Basel, 13 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support Unit and Frontier Science Foundation, announced today stati...
Ten-Year APHINITY Data Show Genentech's Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support U...
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.